NCT01275859

Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer

Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cross-talk between epidermal growth factors and the ER occurs at multiple levels and seems to play a crucial role in breast cancer progression and endocrine resistance.Combined HER1/HER2-targeted therapy with aromatase inhibitors for ER-positive and HER-2 positive postmenopausal breast cancer might enhance response and block emergence of endocrine resistant tumor.

Detailed description

1. To evaluate the efficacy of the neoadjuvant combination therapy with letrozole and lapatinib in postmenopausal patients with ER-positive and HER2-positive breast cancer. 2. To assess markers predictive of treatment response and outcome in this setting.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Letrozole, Lapatinib	Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks

Timeline

• Start date: 2010-09-01
• Primary completion: 2014-04-01
• Completion: 2014-05-01
• First posted: 2011-01-13
• Last updated: 2017-08-29

Locations

1 site across 1 country: South Korea